Drug Type Bispecific antibody |
Synonyms anti-TIGIT/anti-PD-L1 bispecific antibody, HB-0036, HB0036 |
Target |
Action inhibitors |
Mechanism PDL1 inhibitors(Programmed death-ligand 1 inhibitors), TIGIT inhibitors(T cell immunoglobulin and ITIM domains inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Lung Non-Small Cell Carcinoma | Phase 2 | United States | 25 Aug 2022 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 2 | China | 25 Aug 2022 | |
Locally Advanced Malignant Solid Neoplasm | Phase 2 | United States | 25 Aug 2022 | |
Locally Advanced Malignant Solid Neoplasm | Phase 2 | China | 25 Aug 2022 | |
Esophageal Squamous Cell Carcinoma | Phase 1 | United States | 09 Dec 2022 | |
Esophageal Squamous Cell Carcinoma | Phase 1 | China | 09 Dec 2022 | |
Gastroesophageal junction adenocarcinoma | Phase 1 | United States | 09 Dec 2022 | |
Gastroesophageal junction adenocarcinoma | Phase 1 | China | 09 Dec 2022 | |
Hepatocellular Carcinoma | Phase 1 | United States | 09 Dec 2022 | |
Hepatocellular Carcinoma | Phase 1 | China | 09 Dec 2022 |
Phase 1/2 | 19 | whqwtpftfy(xgnznlsjhl) = ≥10% ukmnywekxj (autxexjmdw ) View more | Positive | 24 May 2024 | |||